Cancer glossary
ER and PR on a pathology report: what the percentages mean
What ER and PR mean on a breast cancer IHC report: the 1% cutoff, ‘low positive’ results of 1–10%, why PR matters and how this shapes treatment.
Written and medically reviewed by
Dr. Tara EinullaevaMedical oncologist, 9 years in practice. Credentials · reviewed 17 October 2026
In short
ER and PR are estrogen and progesterone receptors in breast cancer cells. If ER stains in at least 1% of tumor cells, the cancer is considered hormone-sensitive, and hormone therapy is usually part of the treatment plan.
How it appears in your report
The receptors are measured by immunohistochemistry on tissue from a biopsy or surgery. Typical wording:
- ‘ER: 95% of tumor cells, strong staining intensity’ — the share of cells with stained nuclei and how strongly they stain.
- ‘PR: 0%’ — no progesterone receptors.
- ‘ER: Allred 8’ — the same information as a score: the Allred scale combines the share of stained cells with staining intensity, with 8 as the maximum.
- ‘ER: low positive (1–10%)’ — a separate category that should come with an explanatory comment.
What it means
| ER result | Interpretation |
|---|---|
| under 1% | negative |
| 1–10% | low positive (ER-low) |
| over 10% | positive |
About 3 in 4 breast cancers have at least one of these receptors. A tumor with ER and/or PR is called hormone receptor–positive (HR+).
PR is tested in every invasive breast cancer. The ‘low positive’ category is not used for PR. Russian guidelines use a PR cutoff of 20%, which helps decide which luminal subtype the tumor belongs to.
Does it affect treatment
Yes, a lot. For ER-positive cancer, hormone therapy is considered; when both ER and PR are negative, it does not work. With low-positive ER, the evidence is thinner: ASCO/CAP still support offering hormone therapy, while RUSSCO notes that these tumors respond less well. The final plan combines receptors, HER2, Ki-67 and stage, and your treating doctor makes the call. More detail in the article on IHC in breast cancer.
Questions to ask your doctor
- What are my ER and PR percentages, and which subtype does that put my tumor in?
- If ER is 1–10%, how does that change the choice of treatment?
- Should IHC be repeated on the surgical specimen?
If your report has borderline values, I can review your documents in a consultation.
Sources
- ASCO and CAP Release Updated Guideline on Estrogen and Progesterone Testing in Breast Cancer — The ASCO Post (ASCO/CAP), 2020
- Breast Cancer Hormone Receptor Status — American Cancer Society, 2026
- Практические рекомендации по лекарственному лечению рака молочной железы — RUSSCO, 2023
FAQ
Related terms
This is reference information and not a substitute for medical advice. Your doctor interprets each value in the context of your whole situation.
